[20050218]RS22059_允许联邦政府谈判处方药价格的利弊.pdf

上传人:任我行 文档编号:17989 上传时间:2022-06-24 发布时间:2005-09-15 格式:PDF 页数:5 大小:21.82KB
下载 相关 举报
[20050218]RS22059_允许联邦政府谈判处方药价格的利弊.pdf_第1页
第1页 / 共5页
[20050218]RS22059_允许联邦政府谈判处方药价格的利弊.pdf_第2页
第2页 / 共5页
[20050218]RS22059_允许联邦政府谈判处方药价格的利弊.pdf_第3页
第3页 / 共5页
[20050218]RS22059_允许联邦政府谈判处方药价格的利弊.pdf_第4页
第4页 / 共5页
[20050218]RS22059_允许联邦政府谈判处方药价格的利弊.pdf_第5页
第5页 / 共5页
亲,该文档总共5页,全部预览完了,如果喜欢就下载吧!
资源描述

1、1 Section 1860D (i) reads, “NONINTERFERENCE. In order to promote competition underthis part and in carrying out this part, the Secretary (1) may not interfere with the negotiationsbetween drug manufacturers and pharmacies and PDP sponsors; and (2) may not require aparticular formulary or institute a

2、 price structure for the reimbursement of covered Part D drugs.”The conference report adds that, “Conferees expect PDPs to negotiate price concessions directlywith manufacturers.” (H.Rept. 108-391, p. 461)Congressional Research Service? ?The Library of CongressCRS Report for CongressReceived through

3、 the CRS WebOrder Code RS22059February 18, 2005The Pros and Cons of Allowing the FederalGovernment to Negotiate Prescription Drug PricesJim HahnAnalyst in Social LegislationDomestic Social Policy DivisionSummaryThe Medicare Prescription Drug, Improvement, and Modernization Act (MMA)expressly forbids

4、 the Secretary of Health and Human Services (HHS) from negotiatingthe price of prescription drugs on behalf of Medicare beneficiaries. This report outlinesthe arguments for and against allowing the federal government to negotiate prescriptiondrug prices on behalf of Medicare beneficiaries. This repo

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告